CTT Pharma's CEO will issue a Letter to Shareholders

Core Insights - CTT Pharmaceutical Holdings, Inc. is set to release a letter to shareholders on December 2, 2025, detailing strategic initiatives and updates on its S-1 filing to become a full SEC reporting company [1] - The S-1 filing will enable CTT to access funding from its equity line of credit, facilitating growth through the monetization of its patents [1] - The letter will also cover ongoing operational initiatives, including preparations for manufacturing capabilities and updates on strategic partnerships aligned with CTT's commercialization strategy [1] - Shareholders will receive an update on a recently submitted peer-reviewed scientific manuscript that highlights the scientific foundation of CTT's transformative technology in therapeutic drug delivery [2]